77 related articles for article (PubMed ID: 20185939)
21. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C;
J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869
[TBL] [Abstract][Full Text] [Related]
22. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
Motzer RJ; Nichols CJ; Margolin KA; Bacik J; Richardson PG; Vogelzang NJ; Bajorin DF; Lara PN; Einhorn L; Mazumdar M; Bosl GJ
J Clin Oncol; 2007 Jan; 25(3):247-56. PubMed ID: 17235042
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcome of chemotherapy for advanced testicular and extragonadal germ cell tumors: a single-center 27-year experience.
Tanaka T; Kitamura H; Takahashi A; Masumori N; Tsukamoto T
Jpn J Clin Oncol; 2010 Jan; 40(1):73-8. PubMed ID: 19773268
[TBL] [Abstract][Full Text] [Related]
24. Mediastinal metastases from testicular nonseminomatous germ cell tumors: patterns of dissemination and predictors of long-term survival with surgery.
Kesler KA; Brooks JA; Rieger KM; Fineberg NS; Einhorn LH; Brown JW
J Thorac Cardiovasc Surg; 2003 Apr; 125(4):913-23. PubMed ID: 12698156
[TBL] [Abstract][Full Text] [Related]
25. Drug dose delivery and treatment outcome relationship in standard bleomycin, etoposide and cisplatin combination chemotherapy in nonseminomatous germ cell tumor patients.
Gutierrez-Delgado F; Titov DA; Tjulandin SA; Garin AM
Neoplasma; 1999; 46(3):190-5. PubMed ID: 10613596
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial.
Hinton S; Catalano PJ; Einhorn LH; Nichols CR; David Crawford E; Vogelzang N; Trump D; Loehrer PJ
Cancer; 2003 Apr; 97(8):1869-75. PubMed ID: 12673712
[TBL] [Abstract][Full Text] [Related]
27. Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis.
Besse B; Grunenwald D; Fléchon A; Caty A; Chevreau C; Culine S; Théodore C; Fizazi K
J Thorac Cardiovasc Surg; 2009 Feb; 137(2):448-52. PubMed ID: 19185168
[TBL] [Abstract][Full Text] [Related]
28. [High dose chemotherapy with autologous stem cell support in the treatment of germ cell tumors: experience of the centre Léon-Bérard between 1982 and 1996].
Fléchon A; Biron P; Philip I; Blay JY; Droz JP
Bull Cancer; 1999 Apr; 86(4):391-9. PubMed ID: 10341344
[TBL] [Abstract][Full Text] [Related]
29. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
[TBL] [Abstract][Full Text] [Related]
30. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
[TBL] [Abstract][Full Text] [Related]
31. Nondysgerminomatous ovarian tumors: clinical characteristics, treatment, and outcome. A case-controlled study.
Ghaemmaghami F; Hasanzadeh M; Karimi Zarchi M; Fallahi A
Int J Surg; 2008 Oct; 6(5):382-6. PubMed ID: 18715834
[TBL] [Abstract][Full Text] [Related]
32. Testicular function in poor-risk nonseminomatous germ cell tumors treated with methotrexate, paclitaxel, ifosfamide, and cisplatin combination chemotherapy.
Pectasides D; Pectasides E; Papaxoinis G; Skondra M; Gerostathou M; Karageorgopoulou S; Kamposioras C; Tountas N; Koumarianou A; Psyrri A; Macheras A; Economopoulos T
J Androl; 2009; 30(3):280-6. PubMed ID: 19136393
[TBL] [Abstract][Full Text] [Related]
33. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.
Cushing B; Giller R; Cullen JW; Marina NM; Lauer SJ; Olson TA; Rogers PC; Colombani P; Rescorla F; Billmire DF; Vinocur CD; Hawkins EP; Davis MM; Perlman EJ; London WB; Castleberry RP; ;
J Clin Oncol; 2004 Jul; 22(13):2691-700. PubMed ID: 15226336
[TBL] [Abstract][Full Text] [Related]
34. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial.
Droz JP; Kramar A; Biron P; Pico JL; Kerbrat P; Pény J; Curé H; Chevreau C; Théodore C; Bouzy J; Culine S;
Eur Urol; 2007 Mar; 51(3):739-46; discussion 747-8. PubMed ID: 17084512
[TBL] [Abstract][Full Text] [Related]
35. VAB-3 combination chemotherapy in primary mediastinal germ cell tumors.
Vugrin D; Martini N; Whitmore WF; Golbey RB
Cancer Treat Rep; 1982 Jun; 66(6):1405-7. PubMed ID: 6177411
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin-based chemotherapy of primary extragonadal germ cell tumors. A single institution experience.
Gerl A; Clemm C; Lamerz R; Wilmanns W
Cancer; 1996 Feb; 77(3):526-32. PubMed ID: 8630961
[TBL] [Abstract][Full Text] [Related]
37. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
Habuchi T; Kamoto T; Hara I; Kawai K; Nakao M; Nonomura N; Kobayashi T; Ogawa O; Kamidono S; Akaza H; Okuyama A; Kato T; Miki T
Cancer; 2003 Oct; 98(8):1635-42. PubMed ID: 14534879
[TBL] [Abstract][Full Text] [Related]
38. Treatment and prognosis of patients with intracranial nongerminomatous malignant germ cell tumors: a multiinstitutional retrospective analysis of 41 patients.
Ogawa K; Toita T; Nakamura K; Uno T; Onishi H; Itami J; Shikama N; Saeki N; Yoshii Y; Murayama S
Cancer; 2003 Jul; 98(2):369-76. PubMed ID: 12872359
[TBL] [Abstract][Full Text] [Related]
39. Optimal treatment strategy for intracranial germ cell tumors: a single institution analysis.
Kanamori M; Kumabe T; Saito R; Yamashita Y; Sonoda Y; Ariga H; Takai Y; Tominaga T
J Neurosurg Pediatr; 2009 Dec; 4(6):506-14. PubMed ID: 19951035
[TBL] [Abstract][Full Text] [Related]
40. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]